A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.

Overactive Bladder Clinical Trial

Official title:

An Open Label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04485585
• Other study ID #: BR-TMC-CT-101
• Status: Completed
• Phase: Phase 1
• Start date: July 20, 2020
• Est. completion date: August 26, 2020

Study information

• Verified date: October 2020
• Source: Boryung Pharmaceutical Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the influence of BR9006-1 and BR9006-2 on pharmacokinetics, safety, and tolerability when administered separately or co-administered to healthy male volunteers.

Description:

A total of 36 subjects will be enrolled in one sequence group. The investigational products will be administered according to the treatment groups (T, M, T+M) assigned to one sequence group in Period 1, Period 2, and Period 3.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: August 26, 2020
• Est. primary completion date: August 16, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 19 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Subjects are given sufficient explanations about the trial objectives and contents as well as properties of investigational drugs before participating in the trial, and will voluntarily express their consent by signing an IRB-approved written consent to participate in the trial.

2. Healthy male adults aged 19 to 55 years at screening.

3. The subject's weight is 50kg or more and body mass index (BMI) is 18.0 or more but 30.0 or less.

Exclusion Criteria:

1. Those who have history of clinically significant diseases including hypersensitivity reaction, intolerability and anaphylaxis to major ingredients (Tamsulosin and Mirabegron) and other ingredients of investigational products, Food Yellow No. 5 (Sunset Yellow FCF) or Sulfonamide.

2. Those who have a history of clinically significant diseases related to liver, kidney, digestive system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, hemato-oncology system, cardiovascular system (including orthostatic hypotension), etc.

3. Those who have medical history of gastrointestinal system diseases (for example:

Crohn's disease, peptic ulcer disease, etc.) and operations that may influence the absorption of investigational drugs. (However, appendectomy, hernia operation, endoscopic polypectomy and hemorrhoids/anal fissure/anal fistula surgeries are excluded.)

4. Those with abnormal findings from the screening tests (medical interview, vital signs, electrocardiography, physical checkup, blood test, urinalysis, etc.) are judged to have clinical significance.

5. Those who are positive to HBsAg, HCV Ab, HIV Ab, VDRL tests at screening.

6. Those with any of the following results at screening:

• AST or ALT > twice the upper limit of normal range

• T. bilirubin > twice the upper limit of normal range

• Estimated glomerular filtration rate (e-GFR) < 60 mL/min/1.73m2 (MDRD method used)

7. Those with systolic blood pressure > 150 mmHg or < 90 mmHg, or diastolic blood pressure > 95 mmHg or < 60 mmHg from vital signs at screening.

8. Those who took drugs (prescription drugs, OTC, herbal medicine or nutritional supplements (vitamins, etc.)) 2 weeks before screening. (However, those may participate in the trial if their safety and study results are considered to be unaffected according to the investigator's judgment.)

9. Those who have a drug abuse problem (especially centrally acting drugs including sleeping pills, centrally acting pain reliever, opiates or psychoactive drugs) or have a history of drug abuse.

10. Those who have a history of continuous alcohol intake exceeding 21 units/week (1unit=10g=12.5mL) within 6 months before screening.

11. Those who have smoked more than 10 cigarettes a day within 6 months before screening.

12. Those who have participated in other clinical trials and have been administered with other investigational drugs 180 days prior to the estimated administration date of this study's investigational drugs (However, is not applicable if the investigational drugs from other trials are not administered).

13. Those who have given whole blood 8 weeks before screening, who have given plasma/platelet 4 weeks before screening or who have not expressed their consent for blood-donation prohibition between the period from the first administration and 30 days after the final administration of the investigational drugs.

14. Those who have not expressed their consent for diet restrictions (grapefruit, caffeine in particular) that can influence absorption, distribution, metabolism and excretion of investigational drugs in the period between 3 days before the first administration and the last visit.

15. Those who have not expressed their consent for using contraceptive measures (for example: contraceptive administration and implant or intrauterine devices, sterilization (vasectomy, tubal ligation, etc.)) and barrier methods (combined use of spermicides and condom, contraceptive vaginal diaphragm, contraceptive sponge or cervical cap) that are allowed for clinical trials in the period between the first administration of the investigational drugs and the last visit.

16. Others who are judged to be ineligible to participate in the trial by the investigator.

Related Conditions & MeSH terms

• Benign Prostatic Hyperplasia (BPH)
• Hyperplasia
• Overactive Bladder
• Prostatic Hyperplasia
• Urinary Bladder, Overactive

Intervention

Drug:
• BR9006-1
Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose
• BR9006-2
Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose

Locations

Country	Name	City	State
Korea, Republic of	CHA Bundang Medical Center, CHA University	Seongnam-si	Gyeonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
Boryung Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic variables - Maximum (peak) steady-state plasma drug concentration during a dosage interval(Cmax,ss) of Part A and B	The analysis to investigate drug-drug interaction shall be divided into two parts: Part A (Tamsulosin vs. Tamsulosin + Mirabegron) and Part B (Mirabegron vs. Mirabegron + Tamsulosin).	0~26 days after medication
Primary	Pharmacokinetic variables - Area under the plasma concentration-time curve from time zero to time t(AUCt) of Part A and B	The analysis to investigate drug-drug interaction shall be divided into two parts: Part A (Tamsulosin vs. Tamsulosin + Mirabegron) and Part B (Mirabegron vs. Mirabegron + Tamsulosin).	0~26 days after medication
Secondary	Pharmacokinetic variables - Time to reach maximum (peak) plasma concentration following drug administration at steady state (Tmax,ss) of Part A and B	The analysis to investigate drug-drug interaction shall be divided into two parts: Part A (Tamsulosin vs. Tamsulosin + Mirabegron) and Part B (Mirabegron vs. Mirabegron + Tamsulosin).	0~26 days after medication
Secondary	Pharmacokinetic variables - Minimum steady-state plasma drug concentration during a dosage interval (Cmin,ss) of Part A and B	The analysis to investigate drug-drug interaction shall be divided into two parts: Part A (Tamsulosin vs. Tamsulosin + Mirabegron) and Part B (Mirabegron vs. Mirabegron + Tamsulosin).	0~26 days after medication